PCA
ALT icon

Providence Capital Advisors’s Altimmune ALT Stock Holding History

Providence Capital Advisors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-125
Closed -$1K – 318
2022
Q2 		$1K Hold
125
– – ﹤0.01% 270
2022
Q1 		$1K Hold
125
– – ﹤0.01% 408
2021
Q4 		$1K Hold
125
– – ﹤0.01% 320
2021
Q3 		$1K Hold
125
– – ﹤0.01% 286
2021
Q2 		$1K Hold
125
– – ﹤0.01% 292
2021
Q1 		$2K Hold
125
– – ﹤0.01% 254
2020
Q4 		$1K Buy
+125
New +$1.47K ﹤0.01% 303

Other funds holding ALT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Providence Capital Advisors's ALT Position: Q3 2022 in Review

Providence Capital Advisors sold out of Altimmune (ALT) in Q3 2022, closing a stake of 125 shares — an estimated $1K sold.

Providence Capital Advisors first reported a position in ALT in Q4 2020 and held it in 7 quarters. The position peaked at $2K in Q1 2021. 122 funds tracked by Wall St. Rank hold ALT as of Q3 2022.

  • Providence Capital Advisors reported no remaining Altimmune position as of Q3 2022 after selling out during the quarter.
  • Providence Capital Advisors sold 125 Altimmune shares in Q3 2022, an estimated $1K.
  • Providence Capital Advisors first reported a position in Altimmune in Q4 2020 and held it in 7 quarters.
  • Providence Capital Advisors's Altimmune position peaked at $2K in Q1 2021.
  • 122 funds tracked by Wall St. Rank held Altimmune as of Q3 2022.

Based on Providence Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.